A Nomogram Prognostic Model for Advanced Hepatocellular Carcinoma Based on the Interaction Between CD8⁺T Cell Counts and Age

References

• Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6. doi:10.1038/s41572-020-00240-3
   PubMed Web of Science ®Google Scholar
• Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19(3):329–338. doi:10.1055/s-2007-1007122
   PubMed Web of Science ®Google Scholar
• European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. doi:10.1016/j.jhep.2018.03.019
   PubMed Web of Science ®Google Scholar
• Ali R, Gabr A, Abouchaleh N, et al. Survival Analysis of Advanced HCC Treated with Radioembolization: comparing Impact of Clinical Performance Status Versus Vascular Invasion/Metastases. Cardiovasc Intervent Radiol. 2018;41(2):260–269. doi:10.1007/s00270-017-1791-1
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–390. doi:10.1056/NEJMoa0708857
   PubMed Web of Science ®Google Scholar
• Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised Phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–1173. doi:10.1016/S0140-6736(18)30207-1
   PubMed Web of Science ®Google Scholar
• Wong KM, King GG, Harris WP. The Treatment Landscape of Advanced Hepatocellular Carcinoma. Curr Oncol Rep. 2022;24(7):917–927. doi:10.1007/s11912-022-01247-7
   PubMed Web of Science ®Google Scholar
• Llovet JM, Castet F, Heikenwalder M, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2022;19(3):151–172. doi:10.1038/s41571-021-00573-2
   PubMed Web of Science ®Google Scholar
• Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20(11):651–668. doi:10.1038/s41577-020-0306-5
   PubMed Web of Science ®Google Scholar
• Woolaver RA, Wang X, Krinsky AL, et al. Differences in TCR repertoire and T cell activation underlie the divergent outcomes of antitumor immune responses in tumor-eradicating versus tumor-progressing hosts. J Immunother Cancer. 2021;9(1):e001615. doi:10.1136/jitc-2020-001615
   PubMed Web of Science ®Google Scholar
• Minagawa M, Ikai I, Matsuyama Y, et al. Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Ann Surg. 2007;245(6):909–922. doi:10.1097/01.sla.0000254368.65878.da
   PubMed Web of Science ®Google Scholar
• Okuda K, Obata H, Nakajima Y, et al. Prognosis of primary hepatocellular carcinoma. Hepatology. 1984;4(1 Suppl):3s–6s. doi:10.1002/hep.1840040703
   PubMed Web of Science ®Google Scholar
• Wiesner RH, Freeman RB, Mulligan DC. Liver transplantation for hepatocellular cancer: the impact of the MELD allocation policy. Gastroenterology. 2004;127(5 Suppl 1):S261–267. doi:10.1053/j.gastro.2004.09.040
   PubMed Web of Science ®Google Scholar
• CLIP. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology. 1998;28(3):751–755. doi:10.1002/hep.510280322
   PubMed Web of Science ®Google Scholar
• Leung TW, Tang AM, Zee B, et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer. 2002;94(6):1760–1769. doi:10.1002/cncr.10384
   PubMed Web of Science ®Google Scholar
• Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol. 2003;38(3):207–215. doi:10.1007/s005350300038
   PubMed Web of Science ®Google Scholar
• Liu X, Wang X, Yu L, et al. A Novel Prognostic Score Based on Artificial Intelligence in Hepatocellular Carcinoma: a Long-Term Follow-Up Analysis. Front Oncol. 2022;12:817853. doi:10.3389/fonc.2022.817853
   PubMed Web of Science ®Google Scholar
• Yu L, Liu X, Wang X, et al. Nomogram for prediction of long-term survival with hepatocellular carcinoma based on NK cell counts. Ann Hepatol. 2022;27(2):100672. doi:10.1016/j.aohep.2022.100672
   PubMed Web of Science ®Google Scholar
• Jansen CS, Prokhnevska N, Master VA, et al. An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. Nature. 2019;576(7787):465–470. doi:10.1038/s41586-019-1836-5
   PubMed Web of Science ®Google Scholar
• Song Y, Wang B, Song R, et al. T-cell Immunoglobulin and ITIM Domain Contributes to CD8 + T-cell Immunosenescence. Aging Cell. 2018;17(2):e12716. doi:10.1111/acel.12716
   PubMed Web of Science ®Google Scholar
• Linton PJ, Dorshkind K. Age-related changes in lymphocyte development and function. Nat Immunol. 2004;5(2):133–139. doi:10.1038/ni1033
   PubMed Web of Science ®Google Scholar
• Shaw AC, Goldstein DR, Montgomery RR. Age-dependent dysregulation of innate immunity. Nat Rev Immunol. 2013;13(12):875–887. doi:10.1038/nri3547
   PubMed Web of Science ®Google Scholar
• Vogel A, Martinelli E, Vogel A. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. Ann Oncol. 2021;32(6):801–805. doi:10.1016/j.annonc.2021.02.014
   PubMed Web of Science ®Google Scholar
• Giannini EG, Farinati F, Ciccarese F, et al. Prognosis of untreated hepatocellular carcinoma. Hepatology. 2015;61(1):184–190. doi:10.1002/hep.27443
   PubMed Web of Science ®Google Scholar
• Iasonos A, Schrag D, Raj GV, et al. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26(8):1364–1370. doi:10.1200/JCO.2007.12.9791
   PubMed Web of Science ®Google Scholar
• Xiao BB, Lin DF, Sun XS, et al. Nomogram for the prediction of primary distant metastasis of nasopharyngeal carcinoma to guide individualized application of FDG PET/CT. Eur J Nucl Med Mol Imaging. 2021;48(8):2586–2598. doi:10.1007/s00259-020-05128-8
   PubMed Web of Science ®Google Scholar
• Lyu MH, Ma YZ, Tian PQ, et al. Development and validation of a nomogram for predicting survival of breast cancer patients with ipsilateral supraclavicular lymph node metastasis. Chin Med J. 2021;134(22):2692–2699. doi:10.1097/CM9.0000000000001755
   PubMed Web of Science ®Google Scholar
• Liu Q, Li J, Liu F, et al. A radiomics nomogram for the prediction of overall survival in patients with hepatocellular carcinoma after hepatectomy. Cancer Imaging. 2020;20(1):82. doi:10.1186/s40644-020-00360-9
   PubMed Web of Science ®Google Scholar
• Su K, Guo L, He K, et al. PD-L1 expression on circulating tumor cells can be a predictive biomarker to PD-1 inhibitors combined with radiotherapy and antiangiogenic therapy in advanced hepatocellular carcinoma. Front Oncol. 2022;12:873830. doi:10.3389/fonc.2022.873830
   PubMed Web of Science ®Google Scholar
• Li H, Guo L, Su K, et al. Construction and Validation of TACE Therapeutic Efficacy by ALR Score and Nomogram: a Large, Multicenter Study. J Hepatocell Carcinoma. 2023;10:1009–1017. doi:10.2147/JHC.S414926
   PubMed Web of Science ®Google Scholar
• Su K, Guo L, Ma W, et al. PD-1 inhibitors plus anti-angiogenic therapy with or without intensity-modulated radiotherapy for advanced hepatocellular carcinoma: a propensity score matching study. Front Immunol. 2022;13:972503. doi:10.3389/fimmu.2022.972503
   PubMed Web of Science ®Google Scholar
• Li H, Wu Z, Chen J, et al. External radiotherapy combined with sorafenib has better efficacy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Clin Exp Med. 2022;23(5):1537–1549. doi:10.1007/s10238-022-00972-4
   PubMed Web of Science ®Google Scholar
• Philip M, Schietinger A. CD8(+) T cell differentiation and dysfunction in cancer. Nat Rev Immunol. 2022;22(4):209–223. doi:10.1038/s41577-021-00574-3
   PubMed Web of Science ®Google Scholar
• St Paul M, Ohashi PS. The Roles of CD8(+) T Cell Subsets in Antitumor Immunity. Trends Cell Biol. 2020;30(9):695–704. doi:10.1016/j.tcb.2020.06.003
   PubMed Web of Science ®Google Scholar
• Sun YP, Ke YL, Li X. Prognostic value of CD8(+) tumor-infiltrating T cells in patients with breast cancer: a systematic review and meta-analysis. Oncol Lett. 2023;25(1):39. doi:10.3892/ol.2022.13625
   PubMed Web of Science ®Google Scholar
• van der Leun AM, Thommen DS, Schumacher TN. CD8(+) T cell states in human cancer: insights from single-cell analysis. Nat Rev Cancer. 2020;20(4):218–232. doi:10.1038/s41568-019-0235-4
   PubMed Web of Science ®Google Scholar
• Qin S, Xu L, Yi M, et al. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019;18(1):155. doi:10.1186/s12943-019-1091-2
   PubMed Web of Science ®Google Scholar
• Yousefzadeh MJ, Flores RR, Zhu Y, et al. An aged immune system drives senescence and ageing of solid organs. Nature. 2021;594(7861):100–105. doi:10.1038/s41586-021-03547-7
   PubMed Web of Science ®Google Scholar
• Wang S, Shi H, Liu T, et al. Mutation profile and its correlation with clinicopathology in Chinese hepatocellular carcinoma patients. Hepatobiliary Surg Nutr. 2021;10(2):172–179. doi:10.21037/hbsn.2019.09.17
   PubMed Web of Science ®Google Scholar
• Li Q, Cao M, Lei L, et al. Burden of liver cancer: from epidemiology to prevention. Chin J Cancer Res. 2022;34(6):554–566. doi:10.21147/j.issn.1000-9604.2022.06.02
   PubMed Web of Science ®Google Scholar
• Liu J, Wang X, Wang Q, et al. Hepatitis B virus infection among 90 million pregnant women in 2853 Chinese counties, 2015-2020: a national observational study. Lancet Reg Health West Pac. 2021;16:100267. doi:10.1016/j.lanwpc.2021.100267
   PubMedGoogle Scholar
• Saeidi A, Zandi K, Cheok YY, et al. T-Cell Exhaustion in Chronic Infections: reversing the State of Exhaustion and Reinvigorating Optimal Protective Immune Responses. Front Immunol. 2018;9:2569. doi:10.3389/fimmu.2018.02569
   PubMed Web of Science ®Google Scholar